



# ALTEOGEN Inc.

ALTEOGEN, located in Daejeon, South Korea, is a biotech venture company established in 2008. ALTEOGEN has developed proprietary NexP™, NexMab™ and Hybrozyme® platform technologies for long-acting biobetters, site-specific conjugated ADC and novel recombinant human hyaluronidase, respectively. ALTEOGEN aim to transform and improve care for the lives of those who are suffering from serious diseases, in search of therapies with our cutting-edge science and technology. ALTEOGEN was listed on KOSDAQ in 2014.

## Main Products

Product type		Code name	indication	specific indication	Development Stage
Novel Biologics (Biobetter)	Recombinant fusion protein	ALT-P1	Growth hormone deficiency	Growth hormone deficiency	Phase 2
	Antibody drug conjugate	ALT-P7	Oncology	Breast cancer	Phase 1
	Recombinant protein	ALT-B4	Subcutaneous Absorption Accelerator	Oncology	Pre-clinical
Biosimilar		ALT-L9	Ophthalmic diseases	Wet Age Macular Degeneration	Phase 1
		ALT-LS2	Oncology	Breast cancer	Pre-clinical

CEO  
Soon Jae Park, Ph.D.

Location  
62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon, 34054, Korea

- Specialty
1. NexMab™ Technology for site-specific ADC conjugation
  2. NexP™ Technology for long-acting biobetter recombinant therapeutics
  3. Hybrozyme™ Technology for the novel human recombinant Hyaluronidase

Tel / Fax / E-mail  
T. 82-42-384-8780  
F. 82-42-384-8770  
E. info@alteogen.com

## R&D Pipeline

Technology	Pipeline	Research	Process Dev.	Pre-clinic	Phase 1	Phase 2	Phase 3	
NexP™ (Biobetter)	Long-acting hGH, ALT-P1 (hGH deficiency)							
	Long-acting E1-FGF21, ALT-FL1 (NASH)							
NexMab™ (ADC)	Breast/Gastric cancers, ALT-P7							
	Ovarian cancer, ALT-Q5							
Biosimilars	Herceptin® SC biosimilar, ALT-LS2 (Breast/Gastric cancer)							
	Eylea® biosimilar, ALT-L9 (wAMD)							
SC drug delivery	Novel Hyaluronidase (ALT-B4)							